Friday, October 23, 2015

Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene Laherparepvec)

IMLYGIC is First Oncolytic Immunotherapy to Demonstrate Therapeutic Benefit for Patients With Advanced Melanoma



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.